DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation

Table 4 PFS in DLBCL treated by RCHOP-like regime

	PFS	P_value	PFS	P_value
	HR_U(95%CI)	P_value	HR_M(95%CI)	P_value
Age
< 60	1
≥ 60	3.210 (1.376–7.489)	0.007*
BM
Negative	1
Positive	2.764 (0.811–9.425)	0.104
Site
Extranodal	1
Nodal	1.104 (0.484–2.520)	0.813
IHC Hans’ algorithm
GCB	1
Non-GCB	0.731 (0.316–1.690)	0.464
MYC Breakapart
Negative	1
Positive	1.235 (0.166–9.187)	0.836
IPI
Low	1		1
Low_intermediate	1.713 (0.514–5.703)	0.380	1.836 (0.540–6.248)	0.331
High_intermediate	3.103 (0.928–10.375)	0.066	2.291 (0.658–7.982)	0.193
High	9.329 (3.239–26.869)	< 0.001	15.382 (4.722–50.104)	< 0.001
Therapy
RCHOP	1
Resection & RCHOP	0.611 (0.226–1.648)	0.330
CNA_based_clusters
Cluster_1	1
Cluster_2	5.344 (1.639–17.427)	0.005
Cluster_3	0.593 (0.197–1.787)	0.353
Three subgroups of DLBCL
DLBCL_others	1		1
DLBCL_ JAK2/PD-L2_amp	8.846 (2.592–30.198)	0.001	9.246 (2.390–35.774)	0.001
DLBCL_ MYD88_L265P	3.675 (1.428–9.461)	0.007	6.150 (2.153–17.569)	0.001

HR_U hazard ratio by univariate analysis, HR_M hazard ratio by multivariate analysis
* Because age was contained in the IPI, thus it wasn’t put into multivariate analysis

ISSN: 1471-2407